Numerous RCTs evaluated the effects of SGLT2 inhibitors with regard to the improvement of cardio-renal outcomes in patients with diabetes and CKD, and SGLT2 inhibitors have quickly become the standard of care for DKD to delay progression to ESKD, even when the reduction in GFR limits their antihyperglycemic effect. This evidence concerns the gene SLC5A2 and diabetic kidney disease.